- Windtree Therapeutics has announced plans to raise up to $520 million through two funding agreements, with 99% of the funds allocated to purchasing Binance Coin (BNB) as part of its aggressive crypto treasury strategy.
- The move has boosted WINT stock by nearly 5%, signaling strong investor confidence in the company’s blockchain-focused direction.
Nasdaq-listed Windtree Therapeutics (WINT) has unveiled plans to raise up to $520 million to significantly bolster its Binance Coin (BNB) treasury strategy. The move marks a bold shift in corporate treasury management and could signal a broader trend of institutional crypto adoption across non-tech sectors.
According to a recent press release, Windtree has entered into two funding agreements: a $500 million equity line of credit (ELOC) and a separate $20 million stock purchase deal with Build and Build Corp.
Together, these deals will provide the biotech company with substantial liquidity. Notably, 99% of the funds from both agreements are earmarked for purchasing BNB, making Windtree one of the largest publicly traded companies to actively invest in Binance Coin as a strategic asset.
However, there’s one key condition: the company must secure shareholder approval to increase the number of authorized shares before it can use the ELOC funds to acquire BNB. If approved, Windtree could acquire as much as 676,371 BNB based on current prices. At press time, BNB is trading at $761.12, having dipped slightly by 0.15% on the day.
This isn’t Windtree’s first foray into the BNB market. Earlier this month, the company announced a $60 million BNB acquisition as part of a broader securities purchase agreement involving Build and Build Corp and other partners.
These strategic moves appear to be paying off. Since announcing its BNB treasury strategy in mid-July, Windtree’s stock has skyrocketed, up 537.5% over the past six months and 175.6% in the last month alone. On July 25, WINT stock rose 4.87%, now trading at $1.02.
CEO Jed Latkin expressed strong confidence in the firm’s evolving crypto-forward approach.
Pending stockholder approval, the opportunity to secure additional funds for purchasing more BNB cryptocurrency is essential to our strategy,
he said. Latkin also noted that the company will continue exploring new funding avenues to expand its crypto reserves and reinforce its business growth model.
Windtree’s initiative reflects a growing belief that holding digital assets like BNB can offer long-term strategic value, especially as blockchain-based infrastructure becomes more integrated into global finance. While shareholder approval remains a hurdle, success could pave the way for other biotech and traditional firms to explore similar treasury diversification strategies using crypto.
With a $520 million vote of confidence in BNB and the blockchain economy, Windtree Therapeutics may not just be backing Binance Coin, it could be redefining what it means to be a forward-thinking public company in the digital age.
